Dengue is a threat to nearly half the world’s population and is a critical public health priority in over 100 countries in the Americas and in the Asia. Each year, an estimated 500,000 people, including children, have severe dengue requiring hospitalization. However, it has dramatically increased over the past 30 years with speeding up over the last decade. Reported dengue cases in the Americas increased five-fold from 517,617 cases in 2003 to the record level of 2.3 million cases in 2013. According to Indias National Vector Borne Disease Control Programme, until the end of November this year, 90,040 cases were reported from 29 states and six union territories with New Delhi leading the chart.
For the first time ever French pharmaceutical giant Sanofi announced that they got approval from Maxican authority to marketing of DENGVAXIA which is fruit of 20 years of comprehensive research and industrial commitment. It took more than 1.5 billion Euros (USD 1.6 billion) in research and development to create Dengvaxia.
Now dengue is set to become a vaccine preventable disease, said Olivier Charmeil, President and Chief Executive Officer, Sanofi Pasteur. "The data generated from our comprehensive research and clinical program involving 40,000 children, adolescents and adults from 15 countries, will be submitted to the health authorities in countries where dengue is a public health priority.
Sanofi filed for the approval of the vaccine in India last month. The Indian Health Ministry is exploring the possibilities to accelerate the marketing authorization for this preventive vaccine. Dengvaxia is being examined by the Indian drug regulatory agency for exemption from large scale clinical trials on patients. The product is not approved for use in children below the age of nine years but it can immunise two-thirds of people aged nine years and older, rising to 93% for dengue hemorrhagic fever, reducing the risk of hospitalisation by 80%.